Breaking Down Synthetic Biologics, Inc. (SYN) Financial Health: Key Insights for Investors

Synthetic Biologics, Inc. (now Theriva Biologics) trades at $0.1964 per share as of Monday, December 15 (last trade 17:15 PST), and investors face a complex picture: reported 2023 revenues of $5 million with company projections to reach roughly $20 million by 2025 (implying an aggressive ~90% CAGR), yet the firm shows persistent development-stage losses including an EPS of -$1.93 (with forecasts improving toward -$1.08) and an EBITDA loss of -$18.59 million, while balance-sheet dynamics reveal total liabilities rising from $15.52M in 2023 to $16.29M in 2024 and total equity falling from $36.96M to $19.07M-producing a debt-to-equity ratio of 27.21% and a price-to-book of 0.34-so read on to unpack how these revenue forecasts, negative profitability metrics (P/E -0.05; ROE -154.45%), liquidity signals, valuation multiples, development risks, and pipeline-driven growth opportunities could affect your investment stance.

Synthetic Biologics, Inc. (SYN) - Revenue Analysis

• Price: $0.1964 USD
• Change: -$0.02 USD (-0.10%) from previous close
• Latest trade time: Monday, December 15, 17:15:00 PST

• Business model: Clinical-stage biotechnology-primary value drivers are pipeline progress, licensing, and potential future commercialization rather than recurring product sales.
• Reported product revenue: Historically minimal or immaterial; primary reported inflows typically derive from grants, collaborations, or one-time licensing arrangements in filings (check latest 10-Q/10-K for up-to-date figures).
• Expenses and burn: R&D and G&A typically dominate cash outflows; watch quarterly cash burn and cash on hand to estimate runway.
• Key non‑revenue drivers: clinical milestones, partner payments, IP events, and financing activity (dilution risk from capital raises).

• Quarterly revenue disclosures in the next 10-Q/10-K and any collaboration/royalty agreements.
• Quarterly cash balance and burn rate to estimate months of runway.
• Announcements of milestone payments, licensing deals, or commercialization plans that would transition the company toward recurring revenue.
• Financing activity (registered offerings, debt or equity raises) that could dilute holders or alter capital structure.

Synthetic Biologics, Inc. (SYN) - Profitability Metrics

• Reported revenue (2023): approximately $5.0 million.
• No company-disclosed revenue figure for 2024, creating a gap in year-over-year transparency.
• Company-projected revenue (2025): ~ $20.0 million, implying an aggressive multi-year expansion (stated CAGR ≈ 90%).

• Advancement of the oncolytic adenovirus platform and other therapeutic candidates is cited as the principal revenue driver.
• Projected commercialization of clinical-stage assets - timing and regulatory outcomes will determine realized revenue.
• Biotech industry comparables: typical revenue growth ~15-20% annually, underscoring SYN's aggressive growth assumptions versus peers.

• Clinical trial delays, negative efficacy/safety data, or slower-than-expected regulatory progress could materially impair projected revenue realization.
• Dependence on a limited set of product candidates increases binary outcome risk (success vs. failure).
• Absence of a disclosed 2024 revenue figure makes near-term trend validation difficult; interim financing or dilution could impact per-share economics.

• Comparative growth: SYN's projected ~90% CAGR is far above biotech averages (15-20%), which may reflect high upside but also high execution risk.
• Financial due diligence should prioritize clinical milestones, partnership/commercialization agreements, cash runway, and potential funding needs tied to development timelines.
• For profile context and investor interest trends, see: Exploring Synthetic Biologics, Inc. (SYN) Investor Profile: Who's Buying and Why?

Synthetic Biologics, Inc. (SYN) - Debt vs. Equity Structure

• Reported EPS (8/11/2025): -$1.93; consensus forecast for the same period: -$1.08.
• P/E ratio: -0.05, consistent with negative earnings typical of clinical-stage biotech companies.
• Return on Equity (ROE): -154.45%, indicating substantial net losses relative to shareholder equity.
• EBITDA: -$18.59 million, reflecting operating cash-burn from ongoing research and development.

• Equity financing is typical for SYN's stage, aiming to fund clinical trials and precommercial activities while minimizing fixed interest obligations.
• Debt levels are generally kept conservative to avoid covenant pressure on cash-burning clinical programs; interest-bearing liabilities, if present, exacerbate negative ROE and EBITDA impacts.
• Convertible or equity-linked instruments can mitigate near-term cash needs but introduce potential dilution for existing shareholders upon conversion.

• Projected tightening of EPS losses if additional trial starts or expansion occur before revenue generation.
• Potential stock issuance to raise capital could dilute current holders but extend the runway.
• Use of non-dilutive funding (grants, partnerships, milestone-based collaborations) as a stabilizer for both EBITDA and equity value.

Synthetic Biologics, Inc. (SYN): Liquidity and Solvency

• Debt-to-Equity Ratio (2024): 27.21% - indicates moderate reliance on debt financing relative to equity.
• Total liabilities increased from $15.52 million (2023) to $16.29 million (2024), a rise of $0.77 million, signaling a slight uptick in financial obligations.
• Total equity declined from $36.96 million (2023) to $19.07 million (2024), a reduction of $17.89 million, reflecting a materially smaller shareholder equity base.
• The equity decrease is primarily attributable to accumulated losses and continued investments in research and development.
• Relative to the biotechnology industry average, the 27.21% debt-to-equity ratio is low, suggesting a conservative approach to leveraging.
• However, the shrinking equity base could constrain the company's ability to raise additional capital through equity offerings and may increase dilution risk if equity financing is pursued.

• Near-term liquidity considerations: rising liabilities combined with reduced equity increase pressure on cash runway and elevate the importance of successful financing events or milestone-driven inflows.
• Solvency posture: low leverage provides headroom for debt-based financing if needed, but future capital raises may favor debt over equity unless operating performance or cash position improves.

Synthetic Biologics, Inc. (SYN) - Valuation Analysis

• Total liabilities increased from $15.52 million in 2023 to $16.29 million in 2024, indicating a modest rise in financial obligations.
• Total equity declined from $36.96 million in 2023 to $19.07 million in 2024, reducing the equity buffer available to creditors and potentially increasing solvency risk.
• Reported debt-to-equity ratio stands at 27.21%, reflecting moderate leverage and reliance on debt financing relative to equity.
• Key short-term liquidity measures (current ratio and quick ratio) are not disclosed in the available sources, limiting precise assessment of near-term liquidity.

• Valuation implication: the pronounced drop in equity materially affects book value per share and may compress valuation multiples unless offset by improved earnings or cash flows.
• Risk implications: absent explicit liquidity ratios, investors should treat short-term coverage capacity as uncertain and stress-test scenarios for covenant breaches or refinancing needs.
• Debt profile: a 27.21% debt-to-equity ratio suggests manageable leverage for many biotech firms, but the equity erosion raises sensitivity to additional borrowing.

Synthetic Biologics, Inc. (SYN) - Risk Factors

Valuation snapshot and investor-relevant metrics for Synthetic Biologics, Inc. (SYN):

Key valuation observations:

• Share price at $0.1964 places SYN in the low-priced/microcap category, increasing liquidity and volatility risks.
• P/E of -0.05 and EPS estimated at -$3.928 reflect ongoing net losses as SYN advances clinical/development programs - a common stage effect in biotech.
• P/B of 0.34 signals the market is pricing assets at roughly one-third of their book value, suggesting skepticism about asset monetization.
• Negative earnings and a negative P/E should be interpreted in context: many biotechs carry prolonged pre-revenue or loss-making periods while funding R&D and trials.
• Low market cap magnifies the impact of financing, dilution, trial results, and partnership news on per-share value.

Specific risk factors tied to the valuation metrics:

• Funding and Dilution Risk - With negative EPS and limited market cap, SYN may need additional equity or debt financing; such raises can dilute existing holders and pressure the share price.
• Execution Risk - P/B of 0.34 may reflect investor doubts about management's ability to convert R&D assets into approved, revenue-generating products.
• Clinical & Regulatory Risk - Adverse trial outcomes or regulatory setbacks can rapidly widen losses and further depress valuation multiples.
• Market Sentiment & Liquidity Risk - Low-priced stocks can be subject to heightened speculative trading, wider bid-ask spreads, and abrupt price swings.
• Valuation Interpretation Risk - Standard metrics (P/E, P/B) have limited predictive power for early-stage biotech; forward-looking milestones (trial readouts, partnerships, approvals) drive value more than current earnings.

Quantitative sensitivity considerations (example scenarios):

For additional investor context and shareholder composition insights, see: Exploring Synthetic Biologics, Inc. (SYN) Investor Profile: Who's Buying and Why?

Synthetic Biologics, Inc. (SYN) - Growth Opportunities

Synthetic Biologics, Inc. (SYN) operates in a high-risk, high-reward segment of biotechnology where growth is driven by clinical progress, intellectual property, strategic partnerships, and the ability to secure capital. Key growth vectors for SYN include pipeline advancement, licensing or co-development deals, expansion into adjacent indications, and leveraging platform technologies for multiple product candidates.

• Clinical pipeline advancement: successful Phase 2/3 readouts can dramatically re-rate the stock and open licensing or commercialization pathways.
• Partnerships and licensing: co-development or out-licensing deals can provide non-dilutive funding and validation from larger pharma partners.
• Platform expansion: applying core technologies to additional indications can diversify value drivers and reduce single-product dependency.
• Operational scaling: improving manufacturing, reducing COGS, and optimizing trial design to shorten timelines and lower burn.

Investors evaluating Synthetic Biologics, Inc. (SYN) should balance these growth opportunities against the company's risk profile. The most material risk factors include:

• Theriva's reliance on a single therapeutic platform exposes it to risks associated with the success or failure of that platform.
• The biotechnology industry is characterized by high regulatory hurdles, and any delays or rejections in the approval process could adversely affect the company's prospects.
• The company's financial health is heavily dependent on successful fundraising efforts, and any challenges in securing capital could impede its operations.
• Market competition from other biotech firms developing similar therapies could impact Theriva's market share and pricing power.
• The company's stock price is subject to volatility due to market sentiment, clinical trial outcomes, and broader economic factors.
• Theriva's ability to manage operational costs effectively is crucial, as ongoing losses could erode investor confidence and financial stability.

Key quantitative sensitivities investors should monitor:

• Monthly cash burn rate vs. cash on hand - runway = cash / monthly burn.
• Milestone timelines and binary clinical readouts - dates that could trigger financings or partnerships.
• Share count trajectory - recent and potential future issuances that dilute equity.
• Progress on regulatory interactions - IND, CTA, or BLA/NDAs and timelines for approvals.

Further context on the company's history, ownership, mission, and business model can be found here: Synthetic Biologics, Inc. (SYN): History, Ownership, Mission, How It Works & Makes Money